We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Amarantus Obtains European Patent Notice of Allowance Covering Discovery of Lead Protein MANF

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Amarantus Obtains European Patent Notice of Allowance Covering Discovery of Lead Protein MANF"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Amarantus Therapeutics, Inc., a privately-held biotechnology company developing first-in-class disease-modifying treatments that address the underlying cause of cell death, has received a Notice of Allowance from the European Patent Office (EPO).

The patent application claims include the discovery of mesencephalic astrocyte-derived neurotrophic factor (MANF), a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of a range of diseases that includes Parkinson's disease. The patent will broaden overall protection for the Company's therapeutic development of MANF.

The patent claims include compositions of matter and methods of use for MANF, and other related compounds. This new patent complements Amarantus' existing collection of pending patent applications on its proprietary platforms.

"This initial patent allowance from the EPO is a major milestone for the Company's intellectual property pursuits and significantly strengthens our proprietary position in the field," said Martin D. Cleary, Chief Executive Officer. "Moreover, this latest patent will further protect Amarantus' intellectual property as the Company expands its pipeline of first-in-class therapeutics to address a number of indications. Additionally, we will continue to build a strong intellectual property portfolio around our proprietary technology and to further strengthen our leadership position in the emerging field of novel therapeutics."